Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer.

Ban, Hee Jung; Oh, In Jae; Kim, Kyu Sik; Ju, Jin Yung; Kwon, Yong Soo; Kim, Yu Il; Lim, Sung Chul; Kim, Young Chul

doi:2009.66.2.93

Tuberc Respir Dis > Volume 66(2); 2009 > Article

Original Article

Tuberculosis and Respiratory Diseases 2009;66(2):93-97.
DOI: https://doi.org/10.4046/trd.2009.66.2.93 Published online February 1, 2009.

Clinical Efficacy of Belotecan (CKD-602), Newly Developed Camptothecin Analog, in the 2nd Line Treatment of Relapsed Small Cell Lung Cancer.

Hee Jung Ban, In Jae Oh, Kyu Sik Kim, Jin Yung Ju, Yong Soo Kwon, Yu Il Kim, Sung Chul Lim, Young Chul Kim

¹Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea. cyberkks@chonnam.ac.kr
²Department of Pulmonology and Critical Care Medicine, Chonnam National University Medical School, Gwangju, Korea.

Key Words: Belotecan, Camptothecin, Small cell lung carcinoma, Relapse

TOOLS

PDF Links
Full text via DOI
Download Citation
Share :

METRICS

18 Crossref
13 Scopus
6,090 View
22 Download

Related articles

Clinical Study of Topotecan as Second-Line Treatment in Small Cell Lung Cancer.2002 March;52(3)

Phase II Trial of Irinotecan plus Cisplatin Combination as First Line Therapy for Patients with Small cell Lung Cancer.2006 January;60(1)

Phase II Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer.2006 August;61(2)

ABOUT

ARTICLE & TOPICS

Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES

FOR CONTRIBUTORS

Editorial Office: 101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347 Fax: +82-2-572-6683 E-mail: katrdsubmit@lungkorea.org